Thursday March 2, 2017


  • Phosphate and pyrophosphate homeostasis in vascular calcification

    Ricardo Villa-Bellosta, Madrid, Spain

  • Genetics of rare calcifying diseases

    Olivier Vanakker, Gent, Belgium

  • Calciproteins and propensity to calcify

    Andreas Pasch, Bern, Switzerland

  • H2S pathway and calcification

    Sonia Nasi, Lausanne, Switzerland

  • STS and calcinosis

    Korng Ea, Paris, France



  • Regulators of the inflammasome

    Mo Lamkanfi, Gent, Belgium

  • Hyperuricemia driven inflammatory status of the human innate immune system

    Leo Joosten, Nijmegen, Netherlands

  • Nutraceuticals and regulation of obesity and inflammation

    Alexander Haslberger, Vienna, Austria

  • The master metabolic energy sensor AMPK in gout

    Ru Liu-Bryan, La Jolla, USA

  • Targeting the immune-metabolic interface to treat crystal-driven inflammation

    Chris Hall, Auckland, New Zealand

  • Friday March 3, 2017


  • Gout GWAS

    Tony Merriman, Dunedin, New Zealand

  • New efforts to investigate the genetics of hyperuricemia and gout

    Anna Köttgen, Freiburg, Germany

  • Genetics of gout/hyperuricemia: Recent progress from Japan

    Hirotaka Matsuo, Saitana, Japan

  • Epidemiology of gout in Scandinavia

    Lennart Jacobsson, Göteborg, Sweden

  • Gout and Mortality

    Hyon Choi, Boston, USA



  • Managing Gout in the Context of Renal Disease

    Tuhina Neogi, Boston, USA

  • Combining uricosurics with XOI - what is the data

    Fernando Perez-Ruiz, Baracaldo, Spain

  • Update on tophus biology

    Nicola Dalbeth, Auckland, New Zealand

  • The yearly debate: patient education or physician education

    Michael Doherty, Nottingham, United Kingdom

    Till Uhlig, Oslo, Norway

  • Gout directed therapies and comorbidity impact

    Bob Terkeltaub, San Diego, USA